Brian G. Feagan

Research interests

Publications

• Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00061-2

• Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

  ˜The œLancet. Gastroenterology & hepatology · 2023 · https://doi.org/10.1016/s2468-1253(22)00427-7

• IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2023 · https://doi.org/10.1038/s41575-023-00768-1

• Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00466-4

• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00467-6

• Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2022 · https://doi.org/10.1038/s41575-021-00574-7

• Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

  Gastroenterology · 2022 · https://doi.org/10.1053/j.gastro.2022.01.047

• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.01.047

• Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review

  Gut · 2019 · https://doi.org/10.1136/gutjnl-2018-318081

• An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

  Alimentary Pharmacology & Therapeutics · 2018 · https://doi.org/10.1111/apt.14853

• Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

  ˜The œLancet. Gastroenterology & hepatology · 2018 · https://doi.org/10.1016/s2468-1253(18)30233-4

• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1606910

• Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30570-6

• Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

  Gut · 2017 · https://doi.org/10.1136/gutjnl-2016-312735

• Development of an index to define overall disease severity in IBD

  Gut · 2016 · https://doi.org/10.1136/gutjnl-2016-312648

• A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

  The American Journal of Gastroenterology · 2016 · https://doi.org/10.1038/ajg.2016.298

• Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1602773

• The safety of vedolizumab for ulcerative colitis and Crohn's disease

  Gut · 2016 · https://doi.org/10.1136/gutjnl-2015-311079

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  The American Journal of Gastroenterology · 2015 · https://doi.org/10.1038/ajg.2015.233

• Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

  Clinical Gastroenterology and Hepatology · 2015 · https://doi.org/10.1016/j.cgh.2015.06.001

• Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

  Gastroenterology · 2015 · https://doi.org/10.1053/j.gastro.2015.10.041

• SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease

  Gastroenterology · 2015 · https://doi.org/10.1053/j.gastro.2015.01.031

• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(14)60661-9

• Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1215734

• Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1215739

• Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1203572

• Development of the Crohnʼs disease digestive damage score, the Lémann score

  Inflammatory Bowel Diseases · 2010 · https://doi.org/10.1002/ibd.21506

• Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)60304-9

• Certolizumab Pegol for the Treatment of Crohn's Disease

  New England Journal of Medicine · 2007 · 10.1056/nejmoa067594

• A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

  Gastroenterology · 2006 · 10.1053/j.gastro.2006.12.038

• Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa050516

• Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa030815

• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

  The Lancet · 2002 · https://doi.org/10.1016/s0140-6736(02)08512-4

Current projects

No projects listed.